Form 4: Robert Duggan Increases Stake in Pulse Biosciences

Director and 10% owner Robert W. Duggan acquired 660,233 shares of Pulse Biosciences common stock through an at-the-market offering.

Summary

• Robert W. Duggan, a Director and 10% owner of Pulse Biosciences, purchased 660,233 shares of common stock.
• The transaction occurred on May 11, 2026, at a price of $19.69 per share.
• The acquisition was executed through the company's at-the-market (ATM) equity offering program.
• Following this transaction, Mr. Duggan's direct beneficial ownership increased to 48,211,433 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development because significant insider buying typically signals management's belief in the company's intrinsic value, outweighing the minor dilutive impact of the ATM sale.

Positives

• Significant insider confidence demonstrated by the purchase of over 660,000 shares.
• The purchase price of $19.69 reflects the market valuation at the time of the transaction.
• The transaction was conducted in compliance with the company's Insider Trading Policy.

Negatives

• The purchase was made through an ATM offering, which results in dilution for existing shareholders.

Risks

• Reliance on ATM equity offerings to raise capital can lead to ongoing share dilution.
• Market volatility may impact the pricing and success of future ATM offerings.

Future Outlook

The filing indicates the company is actively utilizing its ATM equity offering program to raise capital, suggesting a continued focus on liquidity and funding operations through equity issuance.

Management Comments

• The shares were acquired through the Company's at-the-market equity offering program at the prevailing market bid price or better.

Industry Context

StockSavvy.ai notes that insider buying, particularly from major shareholders like Robert Duggan, is often viewed as a strong signal of confidence in the company's long-term strategic direction, despite the dilutive nature of ATM offerings.

Comparison to Industry Standards

• Insider purchases of this magnitude are generally considered a positive signal compared to industry peers who may rely solely on institutional financing.
• The use of ATM programs is a standard capital-raising mechanism for growth-stage biotech companies to manage cash runway.

Related Party Transactions

• The reporting person holds shares through affiliated entities Genius 24C Inc. and Blazon Corporation.

Stakeholder Impact

• Shareholders may experience slight dilution due to the ATM offering, but the insider purchase provides a floor of confidence for the stock price.

Next Steps

• Continued monitoring of the company's ATM program usage and potential future SEC filings regarding share ownership.

Key Dates

Recommendation

While insider buying is a bullish signal, the reliance on ATM offerings for capital suggests the company is still in a cash-burn phase, warranting a cautious hold until further clinical or commercial milestones are achieved.

Keywords

Pulse Biosciences, PLSE, Insider Trading, Robert Duggan, ATM Offering, Equity Distribution